COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis

Journal of Clinical Immunology

Volumn 26, Issue 1, 2006, Pages 73-85

  Muthian, Gladson ^a   Raikwar, Himanshu P ^a   Johnson, Caroline ^a   Rajasingh, Johnson ^a   Kalgutkar, Amit ^b   Marnett, Lawrence J ^b   Bright, John J ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; COX 2; Cytokine signaling; EAE MS; Th1 cell

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; INDOMETHACIN 4 FLUOROPHENYLAMIDE; INDOMETHACIN BETA HYDROXYETHYLAMIDE; INDOMETHACIN BETA PHENYLETHYLAMINE; INTERLEUKIN 2; JANUS KINASE 2; LM 01; LM 08; LM 11; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; STAT3 PROTEIN; STAT4 PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TH1 CELL;

ANIMALS; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-12; JANUS KINASE 2; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT4 TRANSCRIPTION FACTOR; TH1 CELLS;

EID: 30944463883     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-006-8787-y     Document Type: Article

References (52)

1. Martin R, McFarland HF, McFarlin DE: Immunology of demyelinating disease. Ann Rev Immunol 10:153-169, 1992
2. Dean G: How many people in the world have MS? Neuroepidemiology 13:1-7, 1994
3. Sayetta RB: Theories of the etiology of multiple sclerosis: A critical review. J Clin Lab Immunol 21:55-70, 1986
4. Steinman LR, Martin C, Bernard P, Conlon, Oksenberg JR: Multiple sclerosis: Deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 25:491-505, 2002
5. Donoghue S, Greenlees C: Drugs in development for the treatment of multiple sclerosis: Antigen no-Specific therapies, an update. Expert Opin Investig Drugs 9:167-171, 2000
6. Clegg A, Bryant J: Immunomodulatory drugs for multiple sclerosis: A systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2:623-639, 2001
7. Gold R, Hartung HP, Toyka KV: Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6:88-91, 2000
8. Bright JJ, Musuro, BF, Du C, Sriram S: Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalomyelitis. J Neuroimmunol 82:22-30, 1998
9. Bright JJ, Du C, Coon M, Sriram S, Klaus SJ: Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline. J Immunol 161:7015-7022, 1998
10. Bright JJ, Rodriguez M, Sriram S: Differential influence of interleukin-12 in the pathogenesis of autoimmune and virus-induced CNS demyelination. J Virol 73:1637-1639, 1999
11. Bright JJ, Du C, Sriram S: Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 162:6255-6262, 1999
12. Natarajan C, Bright JJ: Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 3:59-70, 2002
13. Natarajan C, Bright JJ: Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T cells and differentiation of neural antigen specific Th1 cells. J Immunol 169:6506-6513, 2002
14. Muthian G, Bright JJ: Quercetin ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J Clin Immunol 24:541-551, 2003
15. Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis. Brain Pathol 6:243-257, 1996
16. Bradl M, Linington C: Animal models of demyelination. Brain Pathol 6:303-311, 1996
17. Trinchieri G: IL-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific adaptive immunity. Ann Rev Immunol 13:251-276, 1995
18. Trembleau ST, Germann MK, Gately Adorini L: The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16:383-386, 1995
19. Nicoletti F, Patti F, Cocuzza C, Zaccone P, Nicoletti A, Marco Di R, Reggio A: Elevated Serum levels of IL-12 in chronic progressive multiple sclerosis. J Neuroimmunol 70:87-90, 1996
20. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL: Increased IL-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA. 94:599-603, 1997
21. Pagenstecher A, Lassmann S, Carson MJ, Kincaid CL, Stalde AK, Campbell IL: Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J Immunol 164:4481-4492, 2002
22. Leonard JP, Waldburger KE, Goldman SJ: Prevention of EAE by antibodies against interleukin-12. J Exp Med 181:381-385, 1995
23. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM: Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol 15:5258-5267, 1995
24. Darnell JE Jr, Kerr FM, Stark GR: JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421, 1994
25. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE Jr., Murphy KM : Interleukin-12 signaling in Th1 cells involves tyrosine phosphorylation of Stat3 and Stat4. J Exp Med 181:1755-1762, 1995
26. Bacon CM, EM Petricoin 3rd, Ortaldo JR, Rees RC, Larner AC, Johnston JA, O'Shea JJ: Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA. 92:7307-7311, 1995
27. Liblau RS, Singer SM, McDevitt HO: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16:34-38, 1995
28. Conboy IM, DeKrayff RH, Tate KM, Cao ZA, Moore TA, Umetsu DT, Jones PP: Novel genetic regulation of T helper 1 (Th1)/Th2 cytokine production and encephalitogenicity in inbred mouse strains. J Exp Med 185:439-451, 1997
29. Segal BM, Dwyer BK, Shevach EM: An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 187:537-546, 1998
30. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120, 1998
31. Seibert K, Masferrer J, Zhang Y, Gregory S, Olson G, Hauser S, Leahy K, Perkins W, Isakson P: Mediation of inflammation by cyclooxygenase-2. Agents Actions Suppl 46:41-50, 1995
32. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, VanDePutte LBA, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12:1063-1073, 1998
33. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716, 1998
34. Lipsky PE, Isakson PC: Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 24: 9-14, 1997
35. Misko TP, Trotter JL, Cross AH: Mediation of inflammation by encephalitogenic cells: IFN, iNOS and COX-2. J Neuroimmunol 61:195-204, 1995
36. Fretland DJ: Potential role of prostaglandins and Leukotrienes in multiple sclerosis and experimental allergic encephalomyelitis. Protaglandins Leukot. Essent. Fatty Acids 45:249-257, 1992
37. Miyamoto K, Oka N, Kawasaki T, Satoi H, Akiguchi I, Kimura J: The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis. Neuroreport 9:2331-2334, 1998
38. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 12;356:123-126, 2004
39. Bright JJ, Kerr LD, Sriram S: TGF-beta inhibits IL-2-induced tyrosine phosphorylation and activation of JAK1 and STAT5 in T lymphocytes. J Immunol 159:175-183, 1997
40. Bright JJ, Sriram S: TGF-beta inhibits IL-12-induced activation of JAK-STAT pathway in T lymphocytes. J Immunol 161:1772-1777, 1998
41. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 97:925-930, 2000
42. Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ: Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43:2860-2870, 2000
43. Mamett LJ, Kalgulkar AS: Design of selective inhibitors of cyclooxygenase-2 as nonnuclcerogenic anti-inflammatory agents. Curr opin Chem Biol 2: 482-490, 1998
44. Marnett LJ: Forum:reactive species of peroxynitrite. Chem Res Toxicol 11: 709, 1998
45. Marnett LJ, Kalgutkar AS: Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future. Trends Pharmacol Sci 20:465-469, 1999
46. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA: Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 274:22903-22906, 1999
47. Crabtree GR: Contingent genetic regulatory events in T lymphocyte activation. Science 243:355-357, 1989
48. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizonnite R, Gubler U: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147:874-882, 1991
49. Bertagnolli MM, Lin BY, Young D, Herrmann SH: IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol 149:3778-3783, 1992
50. Yanagida T, Kato T, Igarashi O, Inoue T, Nariuchi H: Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol 152:4919-4928, 1994
51. Kennedy MK, Picha KS, Shanebeck KD, Anderson DM, Grabstein KH: Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol 24:2271-2278, 1994
52. Thierfelder WE, van DeursenJM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN: Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174, 1996